$28.280
+1.496 (+5.29%)收盘时
SGP 同业对比
In the context of the broader market, SGP competes directly with industry leaders such as FTH and CLYM. With a market capitalization of $876.34M, it holds a significant position in the sector. When comparing efficiency, SGP's gross margin of N/A stands against FTH's N/A and CLYM's N/A. Such benchmarking helps identify whether SpyGlass Pharma, Inc. is trading at a premium or discount relative to its financial performance.
SpyGlass Pharma Inc 财务表现
The company reported a net loss of $19.9 million for Q2 2026, a significant increase from the previous year, indicating rising expenses. However, the current ratio remains strong at 25.06, suggesting good short-term liquidity.
Financials
FY2026Q2
-21.97M
Operating Profit
FY2026Q1
-13.82M
Net Income after Tax
FY2026Q1
-0.69
EPS - Diluted
FY2026Q1
-14.22M
Free Cash Flow
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。